At Sinotau, our dedication is unwavering in advancing the development, production, and introduction of radiopharmaceuticals that adhere to the highest industry standards in terms of quality, effectiveness, and innovation. Our product portfolio boasts practical applications in the realms of oncology, neurology, and cardiology, underscoring our commitment to pioneering solutions for better healthcare outcomes.
The first radiopharmaceutical targeting β-amyloid approved in China to be used to support early diagnosis of Alzheimer’s disease (AD)
*The information on this page does not constitute commercial promotion of any drug or recommendation of any diagnostic or treatment plan, nor can it replace the advice of a healthcare professional. If you have any questions, please consult a healthcare professional.